WHO Endorses GLP-1 Drugs as Key Tool in Global Obesity Fight
The World Health Organization has issued its first-ever guidelines endorsing GLP-1 weight-loss drugs like Ozempic and Mounjaro as a core treatment for obesity, a chronic disease affecting over a billion people globally.
Key Takeaways
- First WHO Guidelines: The UN health agency now formally recommends GLP-1 agonists for long-term adult obesity treatment.
- Not a Standalone Fix: Drugs must be combined with lifestyle changes, behavioural support, and strong public health policies.
- Massive Scale: Obesity claimed 3.7 million lives in 2022—more than malaria, TB, and HIV combined.
- Access Crisis: High costs and shortages threaten availability, especially in low-income nations.
In a landmark move, the WHO has recognised obesity as a chronic, relapsing disease requiring lifelong care. The new guidance aims to integrate blockbuster GLP-1 therapies into a comprehensive global strategy.
“While medication alone won’t solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus.
Guidelines Stress Integrated Approach
The WHO recommends GLP-1 drugs for adults (excluding pregnant women) but emphasises they are not a silver bullet. The agency calls for pairing medication with intensive behavioural interventions promoting diet and exercise.
“You can’t see these drugs as a magic bullet,” said Dr Jeremy Farrar, WHO Assistant Director-General. “But they’re clearly going to become a very important part of an integrated approach.”
He added that a correct combination could have a “profound” impact on reducing obesity, diabetes, and cardiovascular diseases.
The Staggering Human and Economic Cost
The urgency is stark. WHO data shows over 3.7 million deaths in 2022 were linked to overweight and obesity. Without action, the number of people living with obesity is projected to double by 2030.
The economic burden is equally crushing, predicted to reach $3 trillion annually by 2030. “If we don’t somehow shift the curve, the pressure on health systems is actually going to be untenable,” warned Dr Farrar.
Access and Equity: The Major Hurdle
A critical challenge is ensuring these life-changing drugs reach those who need them most. High prices and supply shortages, even for diabetes patients, have sparked a global access crisis.
In September 2023, the WHO added GLP-1 drugs to its Model List of Essential Medicines, pushing for affordable generic versions in developing countries.
Dr Farrar issued a stark warning on inequity: if innovations like GLP-1s are not made available in middle- and low-income countries, “we are going to increase health inequity over the next generation.”
Senior WHO advisor Francesca Celletti struck a cautiously optimistic note, telling AFP, “There is a possibility that we can bend this epidemiological trajectory of obesity.” The new guidelines mark a significant step in that direction.
